Liquidia Corporation (NASDAQ:LQDA) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 27, BTIG adjusted its price target for Liquidia from $45 to $40 while ...

Liquidia shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.

Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...

In a report released yesterday, Andreas Argyrides from Oppenheimer maintained a Sell rating on Liquidia Technologies, with a price target of $6.00. The company’s shares closed yesterday at $19.26.

Liquidia Corporation (NASDAQ:LQDA) shares have been on a bull run recently, gaining 57% across the past three months, and 27% in the past month. Ostensibly, that may be to do with an upcoming ...

Liquidia's yutrepia was granted tentative approval in 2021 to treat PAH, but the company could not market it due to a regulatory stay related to a patent infringement dispute with United ...

Liquidia lands major victory in patent dispute with United Therapeutics Unlock URL Order Reprints Gift this Article ...

Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients ...

As of June 30, Liquidia had about $103 million in cash, which should support the company into 2024, according to its second quarter report. The company reported revenue of $3.9 million for the ...

Liquidia Technologies is acquiring and then merging with a firm focused on pharmaceutical products to treat rare diseases and also is raising $75 million in a stock offering.

Liquidia had recruited Pope from Boston Scientific. If you put this in perspective of the job from where he came from, he probably got the top job in the world, Nelson said.

Liquidia Corporation LQDA has entered into an exclusive licensing agreement with Pharmosa Biopharm for the development and commercialization of L606 in North America. L606 is an inhaled, twice ...